THIRTY-ONE: Icterus

Clinical Vignette


Missy, a 6-year-old female Shetland sheepdog presents for an acute to subacute onset of weakness, lethargy, poor appetite, and vomiting. Physical examination reveals icteric mucous membranes and mild abdominal tenderness. The initial diagnostics (CBC, urinalysis, and biochemical profile) reveal a packed cell volume (PCV) of 28% (nonregenerative), serum alkaline phosphatase (ALP) of 2,250 U/L, serum alanine aminotransferase (ALT) of 457 U/L, total bilirubin of 14.3 mg/dL, and 4+ bilirubinuria. What is the most likely mechanism for the icterus and what diagnostics would you select next?


Problem Definition and Recognition


Icterus is characterized by hyperbilirubinemia and deposition of bile pigments in tissues, including the blood, skin, and mucous membranes, resulting in a yellowish discoloration of these tissues.


Pathophysiology


Approximately 70% of bilirubin is derived from the death of senescent erythrocytes in reticuloendothelial cells, which occurs mainly in the spleen and liver; another 10% is derived from ineffective erythropoiesis in the bone marrow. Most of the remaining 20% of bilirubin is derived from hepatic cytochromes, catalase, peroxidase, and myoglobin. Bilirubin is the only major breakdown product of heme that requires excretion. The protein and iron components of the heme molecule enter the body pool and are then reused.


Newly formed unconjugated bilirubin is insoluble in water and bound to circulating albumin. In addition to allowing transport of bilirubin via the blood to the liver, binding prevents diffusion of the large bilirubin–albumin complex across cell membranes and thus tends to retain bilirubin in the vascular space. Beyond this capacity, or if binding capacity is reduced, unbound bilirubin may cross cell membranes and enter tissues. Central nervous system toxicity termed kernicterus (rare in animals) occurs in human neonates whenever unconjugated bilirubin crosses the blood–brain barrier, but the toxic effect in older patients is minimal. Bilirubin-binding capacity of albumin may be reduced by (1) decreased plasma albumin, (2) decreased binding sites on the albumin molecule caused by competition for sites by drugs (e.g., sulfonamides or salicylates), and (3) decreased affinity of albumin for bilirubin, caused by acidosis (Center 1996).


Bilirubin dissociates from albumin before entering the liver cell. The flow of bilirubin between plasma and liver is bidirectional, with approximately one-third of the unconjugated bilirubin that enters the liver cell ultimately returning unaltered to the plasma. Hepatic uptake of unconjugated bilirubin is apparently unaffected by severe impairment of hepatic conjugation or excretion of bilirubin. Hepatic uptake of bilirubin is not affected by bile acids. Once inside the hepatocyte, specific proteins termed Y (or ligandin) and Z bind bilirubin. These proteins also bind other anions, such as drugs and steroids (Center 1996).


Hepatic conjugation of bilirubin with glucuronic acid to form bilirubin monoglucuronide and diglucuronide is catalyzed by the glucuronyl transferase enzyme. The importance of conjugation is that bilirubin is transformed from a lipid-soluble to a water-soluble compound. Water solubility is mandatory for excretion of bilirubin in the urine. Lipid insolubility limits back-diffusion of bilirubin into hepatocytes and reabsorption from the intestine, causing it to be excreted through bile into the feces.


Conjugated bilirubin is excreted from the liver cell into the bile canaliculus by a system that appears to have the properties of active, carrier-mediated transport. The transport mechanism involved is different from that for hepatocellular secretion of bile salts. Hepatic excretion of conjugated bilirubin is the rate-limiting step in the overall capacity of the liver to move bilirubin from blood to bile. In contrast to uptake and conjugation, which are well preserved in the presence of hepatocellular injury, the excretory transport system is very sensitive to various types of liver damage. Hence, an increase in plasma-conjugated bilirubin occurs early in the course of hepatocellular injury. However, total plasma bilirubin concentration may not increase until later in dogs with hepatocellular injury, because dogs have a low renal threshold for conjugated bilirubin, and significant bilirubinuria occurs soon after hepatocellular injury. Trace to 1+ amounts of conjugated bilirubin may also appear in the urine of normal dogs, especially in concentrated urine samples. In cats, the renal threshold for bilirubin is slightly higher. Bilirubinuria in cats is nearly always pathologic, indicating either cholestasis or hepatocellular damage (Center 1996).


Bacteria in the lower intestinal tract reduce most of the conjugated bilirubin to a group of chromagens termed urobilinogen. Much of the urobilinogen is excreted in feces, but some is reabsorbed from the colon and carried via portal blood back to the liver. Most urobilinogen is subsequently re-excreted into bile, but a small amount may gain entrance to systemic circulation and be excreted in the urine.


Hyperbilirubinemia and Cholestasis


Bilirubin uptake, conjugation, and excretion are controlled by hepatocellular mechanisms that are separate from the conjugation and excretion of bile acids. Disturbances in bilirubin transport are recognized by hyperbilirubinemia and icterus. Cholestatic syndromes (reduced bile flow) are characterized by marked bile acidemia, usually with normal to slightly elevated bilirubin levels. Severe cholestasis can, however, cause icterus. Measurement of serum bile acids is a reliable procedure for the detection of cholestasis and is also a sensitive test of hepatic function. Once a patient is icteric though, the bile acid measurement yields little information regarding hepatic function since they will reach high levels simply from cholestasis even if hepatocellular function is still normal. Increased serum alkaline phosphatase and gamma glutamyl transpeptidase (GGT) activities also occur with cholestasis (see Chapter 55).


Hyperbilirubinemia may be caused by increases in unconjugated or conjugated bilirubin in plasma. The van den Bergh test has classically been used to fractionate plasma bilirubin into indirect (unconjugated) and direct (conjugated) reacting bilirubin, but this information is usually of little value in determining the etiologic cause of icterus. Since the dog and cat can conjugate bilirubin quite effectively, even in the presence of liver disease, there is too much overlap in the levels of conjugated versus unconjugated bilirubin for this test to be of much value in differentiating causes of icterus.


Unconjugated Hyperbilirubinemia. Increased plasma unconjugated bilirubin can result from increased pigment production (hemolysis or ineffective erythropoiesis) or impaired hepatic uptake or conjugation of bilirubin. Hemolysis accounts for most instances of unconjugated hyperbilirubinemia in icteric dogs and cats and is termed prehepatic icterus. The liver normally has a large reserve capacity for uptake, conjugation, and excretion of bilirubin (30–60 times basal rate). Because of this fact, even with prehepatic causes of icterus (unless it is extremely early in the process), the direct bilirubin levels will almost always be higher than the indirect levels. In addition, it is usually very easy to make a diagnosis of prehepatic icterus without the need for distinction of the type of bilirubin present. In hemolytic icterus, hyperbilirubinemia is initially characterized by a preponderance of unconjugated bilirubin, but dogs and cats have a great capacity to quickly conjugate the bilirubin so that the relative concentrations of conjugated and unconjugated bilirubin may overlap those observed in hepatocellular disease and biliary obstruction. Although the process is incompletely understood, it has been suggested that increases in conjugated bilirubin later in hemolytic icterus may be due to compromise of the excretory system of a previously normal liver injured by anemic anoxia (Center 1996). In this situation, it is assumed that hepatocellular uptake and conjugation of bilirubin remain relatively normal; the lack of excretion would lead to regurgitation from the hepatocyte into blood. Another possible explanation is that excessive hepatocellular production of conjugated bilirubin causes bile inspissation; this would result in intrahepatic biliary obstruction and regurgitation of conjugated bilirubin into blood (Center 1996). It is doubtful that serum alkaline phosphatase activity would help differentiate these two possible mechanisms, since it takes 7–8 days of total biliary obstruction to produce maximum increases of serum alkaline phosphatase. Patients with hemolytic icterus have anemia characterized by signs of regeneration (reticulocytosis, anisocytosis, or poikilocytosis), provided that the bone marrow is functional and 3–5 days have elapsed since the hemolytic crisis (see Chapter 54). If there is intravascular hemolysis rather than extravascular in the reticuloendothelial cells and it is sufficiently rapid, the plasma may be red because of the presence of increased amount of free hemoglobin prior to development of icterus. Normally, a plasma protein referred to as haptoglobin, binds the free circulating hemoglobin and prevents it from entering the urine. With rapid, massive hemolysis, all haptoglobin may be saturated with hemoglobin; the unbound hemoglobin is then filtered by the glomerulus and appears in the urine resulting in red urine (hemoglobinuria). In this instance, there are few if any intact erythrocytes present in the urine to account for the red color or the strongly positive occult blood test results. In addition, one would not expect significant increases in serum levels of leaked enzymes (alkaline phosphatase, GGT) in hemolytic disease. However, anemic anoxia can cause hepatocellular membrane damage and increases in serum ALT. It is possible that biliary obstruction due to bile inspissation, as previously mentioned, could eventually cause increases in serum alkaline phosphatase.


Conjugated Hyperbilirubinemia. Hepatocellular disease and biliary obstruction (intrahepatic or posthepatic) may result in an increase in plasma conjugated and unconjugated bilirubin, with the former predominating. It is difficult to distinguish icterus caused by hepatic disease from icterus due to posthepatic biliary obstruction on the basis of serum chemistry profile data alone. Ongoing hepatocellular disease is often associated with marked increases in serum ALT. Other laboratory abnormalities that may be present with severe hepatic dysfunction include decreased serum concentration of urea nitrogen, albumin, and glucose and increased serum bile acid and plasma ammonia levels. Conjugated bilirubin appears in the urine in increased amounts.


With chronic cholestatic icterus (hepatic or posthepatic causes) the existence of a conjugated bilirubin fraction, which is tightly bound (covalent bonding) to albumin (“biliprotein” complexes) results in an albumin-bound conjugated bilirubin fraction too large to be excreted in urine, its elimination from the body is determined by the half-life of albumin (12–14 days). This results in a delay in clearance of circulating bilirubin and may explain why icterus persists in some patients even after improvement in hepatic function and a disappearance of bilirubin from the urine. In addition, the fat tissues that are saturated with bilirubin in the icteric patient take much longer to clear than the serum. This is why the serum clearance of bilirubin and the yellow discoloration of the serum always precede the clearance of the tissue icterus. Therefore, a patient may be improving clinically in relationship to the disease causing the icterus while maintaining some degree of “tissue icterus.”


Biliary tract obstruction, whether intrahepatic or extrahepatic, is characterized by a marked increase in serum ALP and GGT activities as a result of induced synthesis of these enzymes by hepatocytes and biliary endothelial cells.


Hepatocellular disease and partial biliary obstruction (usually intrahepatic) frequently coexist in patients with liver disease. Bacterial sepsis and endotoxemia may cause impaired hepatic secretion of conjugated bilirubin and decrease bile flow, and therefore increased serum ALP activity and conjugated hyperbilirubinemia may result (Taboada and Meyer 1989).


Cholestasis. Cholestasis refers to decreased bile flow and is characterized by increased serum bile acid levels, ALP and GGT activities, and in more severe cases, by hyperbilirubinemia (Center 1996). Causes of cholestasis include partial or complete biliary obstruction and drug administration. Drugs thought to cause cholestasis in dogs include corticosteroids, phenobarbital, and primidone. Their mechanisms have not been completely worked out, although it is known that long-term use of corticosteroids induces a characteristic hepatopathy in many dogs, characterized by hepatocellular swelling due to accumulation of glycogen and water. Cholestasis probably results from intrahepatic partial biliary obstruction caused by diffuse swelling of hepatocytes.


Diagnostic Plan


History and Physical Examination


Initially, it is important to categorize icterus to one of three basic mechanisms: (1) hemolytic (prehepatic), (2) hepatocellular (hepatic), or (3) obstructive (posthepatic), keeping in mind that combinations of these basic mechanisms frequently occur in clinical disease states (Center 1996). History and physical examination may sometimes suggest one of these categories, but laboratory evaluation is usually necessary (Table 31-1). A clinical pearl is that many times patients with posthepatic causes of icterus may be extremely icteric but yet not appear to be that “ill” clinically. This is in contrast to those patients with prehepatic or hepatic causes of icterus which are icteric and clinically quite ill.


TABLE 31-1. Initial plan for diagnosis of icterus in dogs and cats



















Database Rule-Out* Most Common Findings
History (Hx), physical examination (PE), CBC, reticulocyte count, platelet count, heartworm antigen test (dogs only), urinalysis, biochemical profile including BUN, creatinine, ALT, ALP, total protein, albumin, glucose, total bilirubin, and electrolytes Prehepatic (hemolytic) Hx and PE: Sudden onset of weakness and exercise intolerance, pale mucous membranes with slight to severe icterus, holosystolic mitral murmur common (due to anemia) Lab: PCV <15%, ↑ reticulocytes and NRBCs if 3–4 days since onset, WBC variable, mild bilirubinuria, increased total bilirubin with >50% direct, ALT normal or slightly ↑ (2–5× normal), rest of database normal
  Hepatic Hx and PE: Lethargy, anorexia, vomiting, diarrhea, dehydration, mild to marked icterus Lab: PCV normal or ↑, WBC variable, moderately to markedly ↑ bilirubinuria, increased total bilirubin with >50% direct, ALT moderately to markedly ↑ (5–50× normal), ALP mildly to moderately ↑ (2–10× normal—dog, 2–5× normal—cat), total protein variable, albumin normal or ↓ globulin normal or ↑, BUN normal or ↓
  Posthepatic (obstructive) Hx and PE: Mild to moderate lethargy, variable appetite, occasional vomiting and weight loss, mild to marked icterus Lab: PCV normal, WBC variable, moderately to markedly ↑ bilirubinuria, ↑ total bilirubin with >50% direct, ALT mildly to moderately ↑ (2–10× normal), ALP moderately to markedly ↑ (5–100× normal—dog, 5–15× normal—cat), rest of database variable

CBC, complete blood count; BUN, blood urea nitrogen; ALT, alanine aminotransferase; ALP, alkaline phosphatase; ±, present or absent; PCV, packed cell volume; ↑, increased; ↓, decreased; lab, laboratory; NRBCs, nucleated red blood cells.


*Combinations of these three basic mechanisms of icterus are frequently present in clinical cases.


Laboratory Evaluation


Initial laboratory tests should include a complete blood count (CBC), reticulocyte count if anemia is present, platelet count, heartworm antigen test in dogs, urinalysis, a complete biochemical panel that includes electrolytes (sodium, potassium, chloride), and a fecal occult blood test (Table 31-1). Prehepatic causes are usually apparent on the CBC. If anemia is not present, then prehepatic causes can most likely be ruled out. As a general rule, since the liver has a substantial capacity to metabolize RBC breakdown products and bilirubin, it usually requires a significant anemia (usually <20% and also one which occurs rapidly) for icterus to develop due to this mechanism alone. If mechanisms two or three (see above) coexist with an anemia, then it is not as clear since the patient may be anemic, have icterus, and yet still have a PCV above 20%. The important point to remember is this: if the PCV is not less than 20%, and yet the patient is icteric, then one must be alert to the possibility of multiple mechanisms resulting in the icterus. In addition, the patient may be anemic for one reason (e.g., GI blood loss) and yet have another disorder (such as liver disease) resulting in the icterus. Hepatic and posthepatic causes of icterus cannot be differentiated simply from the above-mentioned laboratory tests. Other diagnostics must be performed to separate these two mechanisms (see below).


TABLE 31-2. Follow-up plan for further diagnostics used to define the cause of icterus in dogs and cats















Rule-Out Database*
Prehepatic (hemolytic) Further drug use history, cytologic examination of blood smears to detect RBC parasites, direct Coombs’ test, antinuclear antibody, blood cultures ±; blood PCR for detection of specific blood parasites (e.g. Babesia spp., Mycoplasma spp.); D-dimers, FDPs, PT, PTT, review blood smear for schiztocytes (all to evaluate for DIC)
Hepatic Abdominal radiographs and ultrasound, repeat biochemistry profile, serum and/or urine bile acids (pre- and postprandial), plasma ammonia levels, serum amylase/lipase ±, feline leukemia virus test (cats only); consider blood cultures, biopsy liver (coagulation panels first) by laparoscopy, ultrasound-guided needle, or celiotomy
Posthepatic (obstructive) Abdominal radiographs and ultrasound, repeat biochemistry profile, serum amylase/lipase ±, canine or feline TLI or PLI, laparoscopy, abdominal CT, consider exploratory celiotomy

TLI, trypsin-like immunoreactivity; PLI, pancreatic lipase immunoreactivity; CT, computed tomography; PCR, polymerase chain reaction; DIC, disseminated intravascular coagulation; FDPs, fibrin degradation products; PT, prothrombin time; PTT, partial thromboplastin time.


*May repeat all or part of initial database (see Table 31.1).


Follow-up diagnostic plans for an icteric dog or cat depend on which category or categories are suspected after results of initial tests are received (Tables 31-2 to 31-4). With hemolytic icterus, a more in-depth history for toxin or drug ingestion is indicated. Careful examination for hemoparasites should be done, as well as a direct Coombs’ test, antinuclear antibody titer, assessment of CBC smear for evidence of spherocytes and reticulocytosis, if autoimmune disease is suspected (see Chapter 54).


Other Diagnostic Procedures


For hepatic and posthepatic causes of icterus, abdominal radiographs and ultrasonography are usually needed to help differentiate these two mechanisms. Serum bile acids (pre- and postprandial) are not useful for this differentiation since they will be elevated in both conditions. It is often helpful to repeat the CBC, serum biochemical analysis, and urinalysis to monitor the dynamic changes that can occur with posthepatic causes. As a general rule, once an animal is icteric from one of these two mechanisms, it is far more likely for the bilirubin levels to continue to elevate with posthepatic disease versus hepatic disease. Abdominal ultrasonography can be very useful to define causes of posthepatic icterus (Gaillot et al. 2007). The finding of a pancreatic mass, gallbladder mass, choleliths, dilated biliary ducts within the hepatic parenchyma, dilated common bile duct, gallbladder dilation, and/or gallbladder mucocele should increase suspicion for a posthepatic cause of the icterus (Neer 1992; Gaillot et al. 2007). If any of these are present, then exploratory laparotomy or laparoscopy may be indicated for diagnostic and therapeutic purposes.


In many cases, laboratory data and radiographic imaging procedures will not define the cause and then fine-needle aspiration, liver biopsy and/or exploratory laparotomy, or laparoscopy is needed. If the liver is noticeably enlarged (extending caudally beyond the ribs), percutaneous needle biopsy or fine-needle aspiration is easy and relatively safe. This procedure is most helpful to definitively define diffuse hepatic neoplasia such as lymphosarcoma, histiocytic sarcomas, lymphoproliferative disease or hepatic lipidosis. Most other hepatic diseases will require wedge biopsy for a definitive answer. If the liver is of normal or small size, biopsy via laparoscopy or celiotomy is preferred. Assessment of hemostasis is always indicated prior to biopsy since coagulation factors are produced by the liver.


TABLE 31-3. Selected causes of icterus in dogs and associated findings


c31_image001.jpg c31_image002.jpg c31_image003.jpg c31_image004.jpg c31_image005.jpg c31_image011.jpg

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

May 25, 2017 | Posted by in SMALL ANIMAL | Comments Off on THIRTY-ONE: Icterus

Full access? Get Clinical Tree

Get Clinical Tree app for offline access